An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Mona Sadat Mirtaleb und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Energy and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), 14965/161, Tehran, Iran; D…. Hauptthemen laut MEDLINE: COVID-19, Viral Vaccines. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute for Genetic Engineering and Biotechnology.
Abstract (Originalsprache)
The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has urged scientists to present some novel vaccine platforms during this pandemic to provide a rather prolonged immunity against this respiratory viral infection. In spite of many campaigns formed against the administration of mRNA-based vaccines, those platforms were the most novel types, which helped us meet the global demand by developing protection against COVID-19 and reducing the development of severe forms of this respiratory viral infection. Some societies are worry about the COVID-19 mRNA vaccine administration and the potential risk of genetic integration of inoculated mRNA into the human genome. Although the efficacy and long-term safety of mRNA vaccines have not yet been fully clarified, obviously their application has switched the mortality and morbidity of the COVID-19 pandemic. This study describes the structural features and technologies used in producing of COVID-19 mRNA-based vaccines as the most influential factor in controlling this pandemic and a successful pattern for planning to produce other kind of genetic vaccines against infections or cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Energy and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), 14965/161, Tehran, Iran; Department of Biotechnology, College of Science, University of Tehran,…
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran; Immunology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: falak.r@iums.ac.ir.
- Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: jalalheshma…
- Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran. Electronic address: b.bakhshandeh@ut.ac.ir.
- Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: taheri@bmsu.ac.ir.
- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: soleim_h@modares.ac.ir.
Förderung
- National Institute for Genetic Engineering and Biotechnology
Zitieren
APA
Mirtaleb, M. S., Falak, R., Heshmatnia, J., Bakhshandeh, B., Taheri, R. A., Soleimanjahi, H., & Zolfaghari Emameh, R. (2023). An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109934
Vancouver
Mirtaleb MS, Falak R, Heshmatnia J, Bakhshandeh B, Taheri RA, Soleimanjahi H, et al. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109934
BibTeX
@article{Mirtaleb2023,
author = {Mirtaleb, Mona Sadat and Falak, Reza and Heshmatnia, Jalal and Bakhshandeh, Behnaz and Taheri, Ramezan Ali and Soleimanjahi, Hoorieh and Zolfaghari Emameh, Reza},
title = {An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109934}
}
EUVIMED